Regulatory Perspective
Recently Published Documents





2021 ◽  
Vol 5 (4) ◽  
pp. 388
Mohd Akhtar Ali ◽  

Qarābādhīn can be termed as pharmacopoeia, contains compiled form of compound formulations or recipes. Importance of Qarābādhīn gradually increased and acquired an imperative status. The history of Qarābādhīn starts from Chiron, Aesculapius, Hippocrates, Dioscorides and Galen in Greco-Roman era. Many of early and medieval Islamic and Arab physicians play vital role and immense original contribution in this discipline and authored important and essential Qarābādhīn with systemic and scientific approaches. Although some of them could not reach the present day, many of the manuscripts can be found in various libraries across the world. Since the Arab Caliphates appreciated and patronized the fields of medicine acquired from Greeks and worked for its development, this period also known as “Greco-Arabic era”. In this work the evaluation of Qarābādhīn (particularly written in Arabic or Greek language) was done in historical and regulatory perspective particularly in Greek era and later on in Medieval Islamic era. The findings of the review indicate the importance and regulatory status of Qarābādhīn and provide information about it. It can be helpful to explore Qarābādhīn and related publications of Greek and Medieval Islamic Arabic period, which gives foundations for the present-day pharmacopeias. Since these documents also take into account ethical considerations, its utility in the fields of medicine and medical ethics should be investigated.International Journal of Human and Health Sciences Vol. 05 No. 04 October’21 Page: 388-404

2021 ◽  
Vol 141 ◽  
pp. 105352
Brian H.W. Guo ◽  
Rory Weston ◽  
Paul Jianphinitnan ◽  
Wanjun Liu ◽  
Eric Scheepbouwer ◽  

Antibiotics ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 648
Michela Pugliese ◽  
Vito Biondi ◽  
Enrico Gugliandolo ◽  
Patrizia Licata ◽  
Alessio Filippo Peritore ◽  

Chelant agents are the mainstay of treatment in copper-associated hepatitis in humans, where D-penicillamine is the chelant agent of first choice. In veterinary medicine, the use of D-penicillamine has increased with the recent recognition of copper-associated hepatopathies that occur in several breeds of dogs. Although the different regulatory authorities in the world (United States Food and Drugs Administration—U.S. FDA, European Medicines Agency—EMEA, etc.) do not approve D-penicillamine for use in dogs, it has been used to treat copper-associated hepatitis in dogs since the 1970s, and is prescribed legally by veterinarians as an extra-label drug to treat this disease and alleviate suffering. The present study aims to: (a) address the pharmacological features; (b) outline the clinical scenario underlying the increased interest in D-penicillamine by overviewing the evolution of its main therapeutic goals in humans and dogs; and finally, (c) provide a discussion on its use and prescription in veterinary medicine from a regulatory perspective.

2021 ◽  
pp. 1-87
Aishwarya Jala ◽  
Srikanth Ponneganti ◽  
Swetha Vishnubhatla Devi ◽  
Gayathri Bhuvanam ◽  
Prithvi Raju Mekala ◽  

Francesca Tomeo ◽  
Segundo Mariz ◽  
Angelo Loris Brunetta ◽  
Violeta Stoyanova‐Beninska ◽  
Karri Penttila ◽  

Vikas Budhwar ◽  
Tarif Hussian ◽  
Manjusha Choudhary ◽  
Garima Saini

Advertisements are essential for sustaining growth and economic development in a world for all kinds of industries. Drug development is a protracted process and a risky business. For new product entry in the market, advertising has a noteworthy positive impact. But some pharmaceutical products advertising specially branded products is controversial and doubtful to advertisement regulations. Advertising is an important asset for any industry to reach new consumers with faith in existing consumers forms over a decade. As per the regulatory perspective in pharmaceutical advertising which is much more than advertising in the serious sense of words itself. The different county has a different legislative framework for protects consumer and company rights. Administrative bodies and lawmakers limit the possibilities of advertising for better achievements. This study emphasizes the regulatory outline of pharmaceutical advertisements in India, USA and Australia.

Export Citation Format

Share Document